Globe Life just reported Q3 2026 results with basic earnings per share of US$4.71 and net income of US$361.1m, and the stock barely flinched. Shares slipped only 0.7% today, hardly a verdict at all on a fresh insurance earnings print of that size.
That muted move matters. The business is generating trailing twelve month earnings of US$1.19b at a P/E of about 10.9x, yet the market reaction looks more like a shrug than a re‑rating. For investors, the real story sits in that disconnect between solid profitability and a cautious price response.
Like Globe Life’s earnings power but uneasy about a stock that barely reacts to a US$1.19b profit stream on a 10.9x P/E? Compare that setup to insurers and financials in our 30 high quality undervalued stocks
Q3 2026 Earnings Summary
- Total Revenue (Q3 2026 vs Q3 2025): US$1,595.9m vs. US$1,513.0m (up about 5.5%)
- Net Income (Excl. Extra Items) (Q3 2026 vs Q3 2025): US$361.1m vs. US$387.8m (down about 6.9%)
- Basic EPS (Q3 2026 vs Q3 2025): US$4.71 vs. US$4.81 (down about 2.0%)
- Combined Ratio (Trailing Twelve Months to Q3 2026 vs Full Year 2025): 59% vs. 55% (a higher ratio, indicating less efficient underwriting over the period)
Look past the headline margin guidance. Ask Charlie what Globe Life isn’t saying about Evry’s losses.
Evaluating Globe Life’s Investment And Buyback Milestones
The bullish view says Globe Life’s story tilts away from premium expansion and toward investment income and aggressive repurchases.
"GL: Premium Growth Is Not The Story, Investment Income And Buybacks Are"
Recent numbers partly line up with that script. Net investment income growth is guided at about 4.5% for 2026, with new fixed-maturity purchases at roughly 6.4% yield, which supports the idea that richer reinvestment rates matter. On capital returns, repurchasing 1.1 million shares for US$185m in Q3 and raising full year buyback guidance under a fresh US$2.5b authorization shows the EPS engine leaning heavily on share count reduction, not just underwriting.
That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for.
Globe Life Bear Case: Health Strains And Buyback Risk
The concern is that Globe Life’s health exposure soaks up efficiency gains and turns buybacks into a risk multiplier instead of a support for earnings.
"Although Globe Life is rolling out broader AI tools across underwriting and administration, the recent rise in health obligations to 56.8% of premium and the drag from higher severity claims and start-up units indicate that efficiency gains may be absorbed by claim volatility."
The latest quarter leans toward that worry. Health premium rose 16%, yet normalized health margin slipped to 20.5% of premium and United American swung to an underwriting loss. Evry’s high severity claims and the CMS processing issue both hit results, while management still stepped up buybacks and trimmed 2026 earnings guidance, which shows the pressure point has not cleared.
Spot Potential Disconnects Early
Globe Life just showed how a solid earnings engine can coincide with a muted share price reaction. The real opportunity sits in spotting stocks that could be undervalued before the market reassesses them.
- Company 1 - 43% below our estimate - focus on scaling newer storage, inverter and software offerings as project delays and interconnection hurdles reshape demand patterns.
- Company 2 - 41% below our estimate - expand manufacturing and supply chain capacity while pushing higher margin window film and installation services through fast growing dealer channels.
- Company 3 - 44% below our estimate - execute a margin improvement plan as software, services and a retooled factory footprint reshape returns across sports and transport display projects.
That is three of the list. See the full list of 30 companies trading below our fair value estimates →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com